Takeda Pharmaceutical Company Limited (TAK) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 5 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $0.28 and revenue of $25.85B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $34.17 vs est $0.28 (beat +12087.2%). Analyst accuracy: 1%.
TAK Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Takeda Pharmaceutical Company Limited in the past 3 months
EPS Estimates — TAK
1%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024
Actual $34.17
vs Est $0.28
▲ 99.2% off
Profitability Outlook
Company is profitable but with thin earnings per share. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — TAK
1%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024
Actual $4,581.551B
vs Est $25.852B
▲ 99.4% off
Revenue Trend
Analysts forecast revenue contraction ahead.
